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A B S T R A C T
Cancer stem cells (CSCs) are a sub-population of tumour cells, which are responsible to drive tumour growth,
metastasis and therapy resistance. It has recently been proposed that enhanced glucose metabolism and immune
evasion by tumour cells are linked, and are modulated by the changing tumour microenvironment (TME) that
creates a competition for nutrient consumption between tumour and different sub-types of cells attracted to the
TME. To facilitate efficient nutrient distribution, oncogene-induced inflammatory milieu in the tumours facil-
itate adaptive metabolic changes in the surrounding non-malignant cells to secrete metabolites that are used as
alternative nutrient sources by the tumours to sustain its increasing energy needs for growth and anabolic
functions. This scenario also affects CSCs residing at the primary or metastatic niches. This review summarises
recent advances in our understanding of the metabolic phenotypes of cancer cells and CSCs and how these
processes are affected by the TME. We also discuss how the evolving TME modulates tumour cells and CSCs in
cancer progression. Using previously described proteomic and genomic platforms, ovarian cancer cell lines and a
mouse xenograft model we highlight the existence of metabolic and immune regulatory signatures in che-
moresistant ovarian CSCs, and discuss how these processes may affect recurrence in ovarian tumours. We
propose that progress in cancer control and eradication may depend not only on the elimination of highly
chemoresistant CSCs, but also in designing novel strategies which would intervene with the tumour-promoting
TME factors.
1. Cancer cell metabolism
Cells need fuel in the form of energy for growth, division and sur-
vival. In normal non-transformed cells, this is attained through the
absorption of nutrients, which are broken down in a series of reactions
through cytosolic glycolysis followed by mitochondrial tricarboxylic
acid (TCA) cycle coupled to oxidative phosphorylation (OXPHOS).
Under normoxic condition, the process of glycolysis generates two
molecules of adenosine 5′-triphosphate (ATP). On the other hand,
several carbon sources such as pyruvate, glutamine, fatty acids (FA),
etc. are fed into the TCA cycle to generate up to 36 molecules of ATP.
Hence, normal cells rely mainly on TCA cycle and OXPHOS as an effi-
cient source of energy. Tumour cells on the other hand, are required to
reprogram their metabolic machinery to meet the enhanced energy
requirement of cell division, increased biosynthesis of macromolecules
for anabolic processes and tight regulation of redox status which they
primarily do through ‘Warburg Effect’ [1]. The glycolytic switch to
Warburg effect is mainly promoted by oncogenes and is inhibited by the
presence of tumour suppressor genes [2]. In addition, tumour cells
communicate with the neighbouring cells in TME to enhance their
metabolic performance on top of cell autonomous metabolic pathways
[3]. Recent literature suggests that even though the bulk of the tumour
cells display dominant Warburg phenotype, most tumour cells possess
intact TCA cycle and OXPHOS [4]. In addition, tumour cells adapt to
amino acid, lipid, FA and cholesterol metabolism for the biosynthesis of
macromolecules for anabolic processes.
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1.1. Oncogenic transformation and cancer cell metabolism
Cancer is a by-product of several oncogenic mutations or a mutation
in a single driver gene and/or loss of tumour suppressor genes, in-
dicating that these phenomena are related to malignant transformation
[2]. We discuss in brief the role of some oncogenes and tumour sup-
pressor genes in cellular metabolism.
1.1.1. The role of p53 in cancer cell metabolism
The p53 gene, frequently mutated in human cancer, acts as a tran-
scription factor and modulates several target genes involved in the
regulation of cell cycle, DNA repair, apoptosis and several other me-
tabolic pathways [5]. Wild-type p53 gene plays a major role in cellular
metabolism and is critical in maintaining the integrity of mitochondria
and OXPHOS, as well as inhibiting glycolysis through suppression of
glucose transporter (Glut)-1 and -4 expressions [5]. In addition, wild-
type p53 regulates glutamine, lipid and cholesterol metabolism through
transcriptional control of glutamine ligase synthetase-2 (GLS2), sterol
regulatory element-binding protein -1 (SREBP-1), sirtulin 1 (SIRT1),
aromatase, acyl-CoA dehydrogenase family member 11 (ACAD11), lipin
1, malonyl-CoA- decarboxylase (MCD), dehydrogenase/reductase 3
(DHR3) and caveolin-1 [5,6]. Hence, loss of p53 activity by mutation or
reduced expression accelerates glycolysis and leads to glutamine and
lipid accumulation in cancer cells, which is metabolised through TCA
cycle to provide fuel for cancer progression.
1.1.2. The role of PTEN in cancer cell metabolism
PTEN is one of the most frequently mutated genes in human cancers
[7]. In animal models, deletion of PTEN leads to the development of
various types of tumours which resembles a range of human cancers
associated with PTEN mutation, indicating its role as a tumour sup-
pressor gene [8,9]. A recent study demonstrated a unique isoform of
PTEN, PTENα, which induces cytochrome c oxidase activity and ATP
production in mitochondria [10]. PTENα also sustains mitochondrial
clearance by directly interacting with parkin E3 ubiquitin ligase
(PRKN), via mitophagy (selective removal of damaged mitochondria by
autophagy) [11]. These observations suggest that PTEN may have a
protective role in mitochondrial biogenesis, a feature that may be lost in
cancer cells.
1.1.3. The role of Myc in cancer cell metabolism
Deregulated expression of Mycis commonly seen in 40% of all
human cancers (www.mycancergene.org) [12]. Myc-transformed cells
have increased glucose and glutamine utilisation through increased
expression of key glycolytic and glutaminolytic enzymes [13]. In ad-
dition, Myc activates the expression of the enzymes ATP citrate lyase
(ACLY), acetyl-CoA carboxylase (ACACA), fatty acid synthase (FASN)
and stearoyl-CoA desaturase (SCD), which are all involved in FA
synthesis from citrate [14]. Hence, Myc regulates glycolysis, OXPHOS
and FA metabolism in cancer cells.
1.1.4. The role of Ras in cancer cell metabolism
Ras protein is mutated in multiple cancers and it activates several
effector pathways to regulate cellular metabolism [15]. K-Ras-trans-
formed tumour cells use ‘Micropinocytosis’ to uptake fuel from tumour
microenvironment for growth [16]. Ras-transformed cells are able to
uptake albumin and exogenous lipids to provide cells with TCA cycle
intermediates for anabolic processes [17]. In pancreatic cancer cell
lines and genetically engineered mouse models, oncogenic K-Ras ex-
pression increased glycolysis through the activation of the Raf/Mek/Erk
pathway [18]. This translational activation led to hexosamine bio-
synthesis pathway (HBP), a precursor needed for glycosylation, and
critical for post-translational modification that has key roles in tu-
mourigenesis [19]. Oncogenic K- Ras also shunts glucose and gluta-
mine-derived metabolites to pentose phosphate pathway (PPP) to pro-
mote ribose biosynthesis and NADPH in cancer cells [20]. In another
context, Ras activation was shown to induce the transcription of pro-
teins catalysing four key steps to enhance glycolysis in cancer cells [21].
These steps are glucose import, hexokinase (HK), phosphofructokinase
(PFK) and lactate export; at least one protein catalysing each of these
four steps is consistently elevated in human tumours.
1.1.5. Heterogenic metabolism in cancer cells
Recent studies in tumour cells have shown that anaerobic glycolysis
in certain population of tumour cells is optional, and OXPHOS and
mitochondrial respiration can occur under certain conditions [3]. Tu-
mour cells encounter variable oxygen levels alternating between nor-
moxic and hypoxic conditions as they disseminate [22]. The enhanced
glycolytic flux and reduced mitochondrial activity in tumour cells
known as ‘Warburg Effect’ commonly arises due to oxygen deprivation.
Subsequently, activation and stabilisation of hypoxia inducible factor-
1α (HIF-1α), promotes the transcriptional activation of Gluts as well as
other glycolytic enzymes and lactate dehydrogenase A (LDHA), which
is responsible for the conversion of lactate to pyruvate [23]. There have
been suggestions that aerobic glycolysis could bestow greater pro-
liferative advantage to tumour cells and make them resistant to spon-
taneous hypoxic stress [24]. In addition, lactate secreted by the tumour
cells is taken up by normoxic cells in a process called ‘Metabolic
Symbiosis’ and converted to pyruvate for oxidation by the TCA cycle.
Hence, cooperation between normoxic and hypoxic cancer cells within
a tumour may maximise efficient energy distribution enabling tumours
to flourish in the TME. It has been proposed that the aerobic glycolysis
in tumour cells provides an advantage as it results in incomplete utili-
sation of upstream intermediates of lactate, which consequently can be
reshuffled towards anabolic processes for macromolecular biosynthesis
required for the rapidly proliferating tumour cells [25]. Another pos-
tulation of this theory is the emergence of acid-resistant tumour phe-
notypes induced by lactic acid production due to enhanced glycolysis in
tumour cells [23]. This acid-resistant tumour population may have
acquired growth advantage enabling them unconstrained proliferation
and tissue invasion [23]. In this context, it has been shown that pan-
creatic, neuroendocrine, breast and renal cancers treated with angio-
genic inhibitors undergo regionalisation into normoxic and hypoxic
zones where cells in the normoxic zones neighbouring the hypoxic areas
undergo ‘Metabolic Symbiosis’ to use lactate diffused from the hypoxic
cells [26]. Lactate utilisation under these conditions is linked to glu-
tamine metabolism through lactate-derived pyruvate transamination.
This reaction allows the production of alanine and α-ketoglutarate (α-
KG) to fuel the TCA cycle, and is dependent on mammalian target of
rapamycin (mTOR) signalling pathway as combined inhibition by an-
giogenic and mTOR inhibitors enables adaptation of normoxic cells to
glycolytic phenotype rendering the hypoxic population devoid of
available glucose.
On the other hand, reliance on OXPHOS rather than glycolysis has
been demonstrated in several tumour models including the orthotopic
mouse model of human glioblastomas [27]. In a subset of melanoma,
melanocyte specific transcription factor (MITF) upregulated the ex-
pression of peroxisome proliferator-activated receptor-γ coactivator-1α
(PGC-1α), which resulted in an increased flux through TCA cycle and
enhanced OXPHOS [28]. PGC-1α-dependent OXPHOS is crucial for
maintaining the growth and survival of this subset of melanomas. These
studies clearly indicate that tumour cells are capable of adapting a
‘metabolic hybrid state’ in which they can use glycolytic or the OXPHOS
pathway depending on the availability of nutrients in TME. It should
also be noted that, besides glucose, mitochondria in tumour cells have
the ability to utilise a broad range of molecules such as glutamine, FAs
and lipids to fuel the electron transport chain for ATP production. For
example, FAβ oxidation (FAβO) was used as a major energy for triple
negative breast cancer [29]. Similarly, glutamine oxidation plays a
critical role in energy production in multiple cancers [30]. As glutamine
is the most abundant amino acid in human plasma it forms an im-
portant additional source of energy, especially when energy from
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glycolytic flux is low.
1.2. Effect of TME on cancer cell metabolism
Tumour-associated metabolic reprograming is not limited to tumour
cells but is also affected by non-malignant cells and cytokines, growth
factors, extracellular vesicles secreted by the non-malignant cells in
TME [31]. The non-cancer component of tumour mostly defined as
‘tumour stroma’ is composed of cancer-associated fibroblasts (CAFs),
endothelial cells, mesenchymal stem cells [MSCs; bone marrow derived
(BM) or carcinoma-associated (CA-MSCs)] and cells from innate and
adaptive immune systems [tumour-associated macrophages (TAMs),
dendritic cells (DCs), myeloid-derived tumour suppressor cells (MDSCs)
conventional T cells (CD4+, CD8+, regulatory T cells) and unconven-
tional T cells [invariant natural killer T cells (iNKT), γδ T cells, mucosal-
associated invariant T cells (MAIT) etc.], B cells, NK cells, etc. Each of
these cellular populations has distinct effect on tumour cell metabolism.
A brief overview is discussed below.
1.2.1. Effect of cancer-associated fibroblasts on cancer cell metabolism
Previous studies nearly two decades ago had shown that when
cancer cells were injected in nude mice in combination with cultured
fibroblasts, tumour growth was significantly accelerated compared to
the growth of tumours injected in mice with cancer cells on its own,
indicating that fibroblasts play a significant tumour-promoting role
[32,33]. The autocrine and paracrine effect of CAFs on cancer cells are
now well studied [34,35]. In pancreatic K-Ras-driven tumours, CAFs
were shown to induce epigenetic and metabolic changes in tumour cells
facilitating tumour progression [36,3]. CAFs-derived cytokines fa-
cilitated glucose uptake in breast cancer cells by increasing the ex-
pression of cell membrane-bound Glut-1 transporter level [37]. Recent
studies have shown that constitutive activation of certain oncogenes [K-
Ras, NFκB, transforming growth factor-β (TGF-β)] and/or loss of tu-
mour suppressor genes (BRCA1) in tumours induced oxidative stress in
neighbouring CAFs which enhanced glycolytic capacity in CAFs, re-
sulting in increased production of lactate, ketones, glutamine, other
amino acids and FAs [38,39]. Lactate and other metabolic fuels pro-
duced by these glycolytic active CAFs were taken up by the neigh-
bouring tumour cells in a process called the ‘Reverse Warburg Effect’ to
increase their tumourigenic potential [38]. This oncogene-driven cou-
pling of CAFs with neighbouring tumour cells was accompanied by a
loss of caveolin-1, autophagy and an increase in lactate mono-
carboxylate transporter (MCT)-4 expression in CAFs. In contrast, tu-
mour cells upregulated MCT-1 for efficient import of lactate and other
mitochondrial fuels to process through TCA cycle and OXPHOS. Me-
tabolically-active CAFs also inhibited oxidative stress in tumour cells by
transferring cysteine, which was converted to glutathione, a powerful
antioxidant that confers resistance to chemotherapy in cancer cells
[40].
1.2.2. Effect of cancer-associated endothelial cells on cancer cell
metabolism
Cancer-associated endothelial cells (CAECs) possess highly pro-
liferative and migratory features and thus have highly activated gly-
colytic mechanism to support their proliferative and anabolic require-
ments [41]. Elevated concentration of lactate in TME influences CAECs
signalling by enhancing interleukin-8 (IL-8)/chemokine (C-X-C motif)
ligand (CXCL) 8 signals to promote angiogenesis [42]. Using small in-
terfering RNA (siRNA) directed against IL-8/CXCL8, it was demon-
strated that tumour cell-secreted lactate stimulated IL-8/CXCL8
pathway which accounts for most of the angiogenic effects of CAECs
[42]. Moreover, the release of lactate by tumour cells has a major
contribution to the development of tumour vasculature, leading to en-
hanced tumour growth, which was inhibited by anti-IL-8 antibody. In
addition, exogenous lactate imported by CAECs also increased vascular
endothelial growth factor (VEGF) A levels through the stabilisation of
HIF-1α and in turn increased endothelial FA uptake through 5′ ade-
nosine monophosphate-activated protein kinase (AMPK), which is cri-
tical for endothelial cell (EC) survival in stress conditions [42]. During
energy-limited states, glutamine contributes to ATP synthesis in ECs
through OXPHOS, indicating that glutamine is used as a fuel by ECs in
conditions of glucose deprivation.
1.2.3. Effect of cancer-associated immune cells on cancer cell metabolism
Glucose metabolism is essential for the proliferation and function of
immune cells [43]. Glycolysis not only provides rapid provision of en-
ergy, but also is critical for post-transcriptional control of interferon γ
(IFNγ) production as well as effector T cell function [43]. Rapidly di-
viding tumour cells restrict access of T cells to glucose, which paves the
way for T cells to undergo metabolic switch to other pathways. It has
been shown that infiltrated CD8+T cells that survived aggressive solid
tumours manage to switch from glucose to FA metabolism [44]. How-
ever, this switch in metabolism requires oxygen, which in growing solid
tumours is limited. Under these conditions, T cells migrate to areas of
normoxia within the tumour to support FAβO, which not only provides
energy through OXPHOS, but also produces ketone bodies that can
serve as nutrients in areas of hypoxia [44]. Apart from glucose defi-
ciency, enhanced accumulation of lactate due to increased aerobic
glycolysis by cancer cells has a detrimental effect on T cell proliferation
and function [43]. Furthermore, lactate strongly inhibits the anti-tu-
mour activity of T effector cells and NK cells [45]. In addition, lactate is
preferentially consumed by regulatory T cells (Tregs) causing T cell
polarisation to Tregs in the TME [43]. Excess lactate in TME also leads
to MI macrophage polarisation to M2 phenotype further promoting
tumourigenesis [45]. Recent studies have shown that TILs from pro-
gressing tumours are glucose-restricted and have impaired function
compared to TILs from regressing tumours, which have adequate glu-
cose intake [46]. In another scenario, treatment of tumour bearing mice
with checkpoint inhibitors (anti-CTLA-4, PD-1 and PD-L1 antibodies)
has shown to restore glucose availability in TME, permitting T cell
glucose metabolism and function [46]. These studies indicate that tu-
mour-imposed metabolic restriction in T cells makes them functionally
unresponsive for anti-tumour activity, and can be relieved by strategies
through restoration of glucose consumption in T cells.
In addition to glucose, tryptophan and arginine are required for T
cell proliferation and activation. Indolamine 2, 3-dioxygenase (IDO) is a
key enzyme involved in tryptophan catabolism. Upregulation of IDO
expression correlates with several malignancies and has been associated
with low T cell infiltration and reduced survival in colon cancer [47].
Enhanced expression of IDO in tumour cells depletes tryptophan
availability in TME and impedes T cell function. IDO contributes to the
degradation of tryptophan to kynurenine, accumulation of which in
TME leads to immunosuppression through downregulation of T cell
receptor CD3ζ-chain and induction of Treg differentiation [48]. Argi-
nine depletion occurs in arginase (ARG) or nitric oxide (NO) synthase
overexpressing tumours, subsequently leading to unresponsive T cells
[49]. Arginine depletion blunts T cell function and results in the gen-
eration and infiltration of myeloid-deprived suppressive cells that fur-
ther adds to the immunosuppressive TME [50].
2. Cancer stem cells
The concept of a rare population of cancer stem or initiating cells
(CSCs) within a poorly differentiated tumour mass that contributes to
drug resistance and is responsible for tumour recurrence and further
metastasis is established. However, further investigation is crucial to
make essential discoveries for effective cancer control and treatment
[51,52]. Current cancer treatments target rapidly proliferating cancer
cells in order to eradicate tumour burden and relieve cancer-associated
symptoms. However, CSCs because of their assumed quiescent pheno-
type are resistant to current standard therapies. As a result, CSCs persist
as a minimal residual disease even after effective anti-cancer drug
N. Ahmed et al. Seminars in Cancer Biology 53 (2018) 265–281
267
treatments, which presumably eliminates substantial component of
bulk of the tumour. It is thus believed, that residual CSCs after initial
anti-cancer treatment are responsible for cancer relapse and recurrence,
which ultimately leads to patient mortality.
The ‘clonal evolution’ theory first described in 1970s postulates that
during the course of malignant transformation, tumour cells attain ge-
netic mutations that results in the selection of sub-clonal population of
cells with differential phenotypes and malignant potential resulting in a
heterogeneous tumour [53]. On the other hand, the CSC-model pro-
poses that the initiation and progression of tumours is driven by a small
population of cells, each of which has distinct mutational profile and
epigenetic changes which when combined, has the potential to form
bulk of the tumour [51,54]. In addition, it has been proposed, that CSCs
are organised in a hierarchical manner with a subset of tumour cells
with CSC-like properties possessing the potential for self-renewal and
aberrant differentiation residing at the apex [52]. Epigenetic changes
that mimic normal differentiation have been proposed to regulate the
generation of these hierarchically arranged clones, which share
common mutational changes but have diverse genetic profiles and
functions [55]. Recent evidence suggests that CSCs may arise from
metabolic changes occurring in non-CSCs [56]. Certain metabolic
changes that affect chromatin organisation and activate epigenetic
changes may regulate metabolic-driven CSCs [56]. In that context,
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs)
have shown to exhibit traits such as immortal cell growth and high
proliferation rates under appropriate culture conditions similar to
cancer cells [57]. Additionally, both ESCs and iPSCs give rise to ter-
atomas after transplantation into immunocompromised mice [58], and
are reprogramed by transcription factors such as c-Myc, Klf4, Sox2,
Lin28 and Oct4, which are highly expressed in many cancers [59]. This
suggests that certain aspects of somatic cells reprograming and tu-
mourigenesis rely on common mechanisms. Consistent with that, a re-
cent study has shown that c-Myc potentiates the glycolytic capacity of
iPSCs [60]. Enhanced glycolytic capacity and inhibition of OXPHOS in
iPSCs promotes stemness, while suppression of glycolysis inhibits pro-
liferation leading to cell death [60].
2.1. Cancer stem cell metabolism
Due to their undifferentiated phenotype, it is accepted that CSCs
have enhanced glycolytic phenotype compared to differentiated cells
that rely mostly on OXPHOS [61]. In addition to glycolysis and classical
OXPHOS phenotypes, CSCs also utilise FAβO and glutaminolysis which
occurs through mitochondrial respiration [62,56]. A recent study on
lung and ovarian cancer models has shown a generation of CSCs with a
high telomerase activity that demonstrated enhanced glycolysis as well
as increased OXPHOS [63]. Not only did these particular CSC subtypes
show increased mitochondrial mass, but they also displayed enhanced
stemness properties, cell proliferation and migration, which were in-
hibited by classical inhibitors of glycolysis and mitochondrial biogen-
esis [63]. Recent studies have suggested that metabolic plasticity exists
in the CSCs of certain cancer subtypes, or may coexist within the same
cell type thus contributing to metabolic heterogeneity [62]. This notion
is associated partly with iPSCs reprograming which is initiated by
transcription factors Sox2, Oct4, Klf4 orMyc, and subsequently switches
the metabolic flux from OXPHOS to glycolysis.
Metabolic plasticity in stem cells is also regulated by their pro-
liferative states [62]. For instance, dormant haemopoietic stem cells
(HSCs) utilise the glycolytic pathway to attain energy in the hypoxic
niches [64,65,56]. Mitochondrial biogenesis and activity is repressed
under these conditions to maintain HSC in a dormant state [66].
However, when dormant HSCs are allowed to rapidly proliferate, as
shown by targeted mutation in tuberous sclerosis complex 1 (TSC1), a
negative regulator of mammalian target of rapamycin (mTOR) com-
plex, a massive increase in HSC proliferation is observed concomitant
with mitochondrial biogenesis, reactive oxygen species (ROS)
production and upregulation of OXPHOS genes [67,56]. These studies
suggest that the transition of HSCs from a dormant to an active pro-
liferative state relies on a metabolic shift from glycolysis to an OXPHOS
phenotype. In the case of CSCs, this transition may occur in response to
DNA, cellular damage, or other adverse environmental stress (e.g. hy-
poxia, nutrient deficiency, etc). Hence, metabolic plasticity in stem cells
relies not only on the biochemical intrinsic needs of the cells, but is also
dependent on the environmentally triggered stressors that may shift the
metabolic pattern. The metabolic plasticity of CSCs has been described
in a few recent reviews summarised below [56,62,68,69].
2.1.1. Evidence of glycolytic phenotype in CSCs
Comparison of the glycolytic capacities between CSCs and non-CSCs
has shown that CSCs have elevated glucose consumption, lactate
synthesis and ATP production compared to non-CSCs of the same
origin, suggesting enhanced glycolysis in CSCs [62]. Elevated expres-
sion of oncogenic Myc expression is the main driver of stemness and
glycolytic flux in certain types of breast cancer, nasopharyngeal and
hepatocellular carcinomas [12,62]. This was also true for
CD44+CD24lowEPCAM+basal-like breast CSCs where metabolic switch
from OXPHOS to glycolysis was shown to enhance stemness and CSC
properties by reducing ROS [70,62]. In addition, glycolysis was found
to be the preferred metabolic program in radio-resistant sphere forming
nasopharyngeal CSCs [71] and CD133+CD49f+ CSCs in hepatocellular
carcinomas [62]. In pancreatic ductal adenocarcinoma, CSC phenotype
is also dependent on glycolysis as 3-bromopyruvate, an inhibitor of
glycolysis, decreased self-renewal of aldehyde dehydrogenase 1+
(ALDH+)-enriched CSCs and reverted gemcitabine resistance [72].
Oncogenic transcription factor signal transducer and activator of
transcription 3 (STAT3) is constitutively active in many cancers
[73,74]. Given the importance of the constitutively active STAT3 in the
survival of many types of CSCs [75–77], it is important to determine the
status of cellular metabolism of STAT3-dependent CSCs. Recent studies
indicated that constitutively active STAT3 (Tyr 705) induces a meta-
bolic switch to aerobic glycolysis and downregulates mitochondrial
activity in primary fibroblasts and other STAT3-dependent tumour cell
lines [78]. STAT3-induced glycolysis is dependent on HIF1-α upregu-
lation, while the downregulation of mitochondrial oxidation is in-
dependent of HIF1-α regulation and occurs due to the downregulation
of STAT3-associated mitochondrial proteins [78]. The induction of
aerobic glycolysis is important for STAT3 oncogenic activity, as in-
hibition of STAT3 tyrosine phosphorylation (Tyr705) downregulated
glycolysis leading to growth arrest and cell death, in vitro and in an in
vivo mouse model [78]. We have demonstrated that blocking Janus
kinase 2 (JAK2)/STAT3 also inhibited CSC-renewal and tumour growth
in vivo [79–81].
2.1.2. Evidence of OXPHOS phenotype in CSCs
Recent studies suggested that certain sub-types of CSCs have an
increased mitochondrial mass and membrane potential resulting in an
overall increased mitochondrial function [82,83]. This increased mi-
tochondrial mass in a subpopulation of breast cancer was shown to
induce stem-like properties resulting in heightened metastatic potential
and resistance to DNA damage [83]. Majority of the ROS produced in a
biological system comes from mitochondrial respiration. Furthermore,
redox homeostasis is critical for balancing self-renewal and differ-
entiation of normal stem cells and CSCs. Stem cells have low levels of
ROS and high expression of antioxidant genes to dispose ROS and
protect cells from oxidative insult [84]. For instance, CSCs from pri-
mary gliomas, CD133+ CSCs from glioblastomas and pancreatic cancer
preferred OXPHOS to glycolysis for energy production [85–87]. In
CD133+ glioblastomas, the metabolic shift to OXPHOS was orche-
strated by insulin-like growth factor 2 mRNA binding protein (IMP2),
which directly interacts with several mitochondrial complex genes and
regulates stemness markers including CD133, Sox2, Oct4 and Nanog
[86]. While in CD133+ pancreatic cancer, OXPHOS was maintained by
N. Ahmed et al. Seminars in Cancer Biology 53 (2018) 265–281
268
the expression of peroxisome proliferator-activated receptor-γ coacti-
vator-1α (PGC-1α) transcription factor resulting in enhanced OXPHOS
[87].
Besides glucose, CSCs also rely on mitochondrial FAβO for ATP and
NADPH generation. A very recent study has demonstrated that the JAK/
STAT3 pathway regulates lipid metabolism through FAβO to promote
breast CSCs and chemoresistance [29]. Inhibiting JAK/STAT3 blocked
breast CSC self-renewal and expression of several lipid metabolic genes
including carnitine palmitoyl transferase 1B (CT1B), the critical enzyme
for FAβO [29]. FAβO has been shown to be important for the main-
tenance of HSCs and CD8+ memory T cells, which exhibit stem cell-like
phenotype [88,89]. FAβO inhibition in HSCs has been shown to deplete
stem cell population while in the case of T cells, it blocks T cell dif-
ferentiation towards memory T cell lineage [88,90]. These data suggest
that FAβO pathway may favour CSC sustenance rather than rapid
proliferation.
2.2. Effect of TME on CSC metabolism
Analogous to normal stem cells which are regulated by their ‘ni-
ches’, CSCs are also regulated by their TME and in turn regulate other
cells in the TME [51]. Strong expression of HIF-1 and -2α coincides
with high levels of stem cell-associated genes in tumour cells located in
the hypoxic regions of clinical samples [91,92]. HIF-1α has been shown
to activate the expression of stem cell- associated transcription factor
Oct4 through Notch signalling, suggesting that hypoxia can enhance the
propagation of CSCs [93]. Moreover, HIF-2α facilitates the release of
angiogenic factors and promotes acquisition of a CSC-like phenotype in
glioblastomas [91]. We discuss in brief the effect of TME-associated
cells on CSC metabolism.
2.2.1. Effect of cancer-associated fibroblasts on CSC metabolism
High densities of CAFs at the invasive fronts of epithelial tumours
are thought to control the invasion of tumours [94]. A population of
CD44+CD90+ CSCs has been shown to reside in direct contact with
CD90+ CAFs at the periphery of invasive nests of breast tumours [95],
suggesting a potential role of CAFs in sustaining the invasive phenotype
of CSCs. Similarly, pancreatic stromal cells facilitate the self-renewal
and invasive properties of pancreatic CSCs [96]. Hedgehog (Hh) sig-
nalling, which is crucial for leukaemia-CSCs, has been shown to be
regulated by stromal cells via the expression of Hh-interacting protein
[97]. In this context, the process of ‘Metabolic Symbiosis’ as described
for cancer cells also exists to facilitate the interaction of CSCs with
surrounding CAFs. In TME, tumour cells, CSCs and CAFs express dif-
ferent types of lactate MCTs. It has been suggested that epithelial tu-
mour cells with CSC-like phenotype express MCT-1, while CAFs and the
rest of the non-CSC tumour cells express MCT-4 [98]. MCT-4-positive
hypoxic CAFs and tumour cells secrete lactate by glycolysis, which is
taken up by MCT-1 expressing epithelial CSC-like cells that use lactate
as a substrate for TCA cycle [99]. This activated mitochondrial meta-
bolism provides enough energy for CSC self-renewal, invasion and
metastasis. Co-culture studies of cancer and CAFs have shown that CAFs
have increased expression of glutamate ammonia ligase, a key enzyme
for glutamine synthesis [100]. CAF-derived glutamine was found to
increase mitochondrial OXPHOS in cancer cells by decreasing their
autophagy [101]. In this context, mesenchymal stem cells (MSCs) iso-
lated from the pleural effusion or ascites of lung, breast and ovarian
cancer patients have shown to transfer glutamine to tumour cells for
energy and biomass production [102].
The interaction between tumour cells and stromal cells in TME can
also lead to epithelial- mesenchymal transition (EMT) which is required
for cell growth and invasion [103]. The induction of EMT is involved
with the procurement of CSC properties, resulting in reduced mi-
tochondrial metabolism and enhanced glycolytic flux [104]. Many EMT
and CSC regulators such as Snail, Dlx-2, HIF-1, STAT3, TGF-β, Wnt and
Akt are associated with the metabolic reprograming of cancer cells
[105]. TGF-β and Wnt inhibit mitochondrial activity and enhance
glycolysis by activating Dxl-2 and Snail through suppression of mi-
tochondrial complex IV [104]. Wnt inhibits pyruvate dehydrogenase
kinase (PDK1), thus promotes glycolysis and inhibits OXPHOS [106]. In
addition, several glycolytic enzymes, including pyruvate kinase M2
(PKM2), lactate dehyrogenase (LDH) and pyruvate carboxylase (PC)
have been associated with the induction of EMT and CSCs
[105,107–109]. PKM2 is a less active form of pyruvate kinase usually
expressed in ESCs and cancer cells. Low activity of PKM2 in these cells
shifts the metabolism from OXPHOS to aerobic glycolysis. Moreover,
EMT-induced TGF-β stimulus triggers nuclear translocation of PKM2,
allowing interaction of nuclear PKM2 with TGF-β induced factor
homeobox-2 (TGIF2), which represses TGF-β signalling by recruiting
histone deacetylase 3 to E-cadherin promoter to suppress E-cadherin
transcription [107]. In addition, high levels of LDHA (a dominant form
of LDH) is positively correlated with the expression of EMT and CSC
markers in bladder cancer cell lines and muscle invasive bladder cancer
specimens [109]. These observations suggest an important role of gly-
colysis in inducing EMT and CSC phenotypes in cancer.
On the contrary, the respiratory enzymes citrate synthase (CS),
succinate dehydrogenase subunit B (SDHB) and gluconeogenesis reg-
ulatory enzyme fructose bis-phosphate (FBP) have been shown to ne-
gatively regulate EMT and CSC phenotypes [70,110,111,105]. CS is a
mitochondrial enzyme involved in the first step of the TCA cycle. Loss
of CS induces EMT and glycolysis with concomitant upregulation of
Snail and Twist, and downregulation of p53 and its target genes
[105,110]. Reactivation of p53 on the other hand, inhibits CS-knock-
down-induced EMT, suggesting a critical role of p53 in these metabolic
alterations. SDH is a mitochondrial enzyme; it converts succinate into
fumarate in the TCA cycle and catalyses the transfer of electron through
the electron transport chain. Knockdown of SDHB promotes EMT by
altering glucose and glutamine utilisation and inducing mitochondrial
dysfunction [105,111]. In addition, loss of FBP through Snail-induced
epigenetic changes enhanced glycolysis-induced EMT and CSC pheno-
types [70]. In addition to glycolysis and TCA cycle, inhibition of glu-
tamine metabolism through knockdown of glutaminase 1, an enzyme,
which converts glutamine to glutamate, suppresses DLx-2-, TGF-β−,
Wnt- and Snail-induced EMT and, metabolically switches to glycolytic
pathway to maintain flux of energy fuels [112,105]. Furthermore,
mutual regulation of FA synthase (FASN), an enzyme that regulates FA
synthesis and TGF-β contributes to EMT/CSC phenotype in cisplatin-
resistant non-small cell lung cancer [113].
2.2.2. Effect of cancer-associated endothelial cells on CSC metabolism
The complex process of angiogenesis during tumour progression
requires recruitment of endothelial progenitor cells in TME where they
differentiate into blood vessels to carry oxygen and nutrients to rapidly
progressing tumours [114]. Under these circumstances, glycolysis, for
faster ATP generation, is the preferred pathway in ECs [115–117]. In
two recent studies on glioblastomas, CSCs were shown to differentiate
into ECs in a process called ‘vascular mimicry’, generating their own
vasculature through VEGF-dependent pathway [118,119]. VEGF sig-
nalling sustains vascular niche in controlling stem cell characteristics in
a diverse range of cancers [120,121]. IL-6 secreted by tumour-asso-
ciated ECs was also shown to be essential for maintaining CSC char-
acteristics in head and neck squamous CSCs [122]. Tumour formation
was inhibited when ALDHhigh/CD44high head and neck squamous
CSCs were co-injected with ECs stably transfected with shRNA IL-6 or
when tocilizumab used to target IL-6 receptor [62,122]. VEGF was
shown to support angiogenic switch mainly by stimulating the glyco-
lytic pathway [115,116]. The efficiency of angiogenesis was reduced
when the glycolytic pathway was inhibited by the knockdown of fruc-
tose-2,6-bisphosphatase 3 (PFKFB3), a rate limiting enzyme in the
glycolytic pathway in endothelial cells [62,116]. Few recent studies
have shown that VEGF stimulates mitochondrial metabolism through
complimentary Akt and PGC-1α pathways [123,124]. Given its
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prominent role in angiogenesis, VEGF has been a target for many anti-
angiogenic therapies [125]. However, the addition of these anti-an-
giogenic agents to standard cytotoxic chemotherapy regimen has not
provided expected results in terms of patient survival [126]. These
observations in patients are supported by studies in mouse models and
human samples that show that anti-angiogenic agents increase cancer
invasion and metastasis by generating tissue hypoxia and increased
numbers of CSCs [127]. Anti-angiogenic agents also enhance stromal
cell recruitment to hypoxic regions where they secrete growth factors
and cytokines indirectly resulting in therapy failure [127].
2.2.3. Effect of cancer-associated immune cells on CSC metabolism
The immune system exerts both inhibitory and stimulatory effects
on progressing tumours and a balance in these two opposing effects
dictates the growth and progression of tumours [45]. Tumour- asso-
ciated macrophages (TAMs) are innate immune cells which are present
in large numbers in TME and play an active role in tumourigenesis
[45,128,129]. Under the influence of inflammatory TME, macrophages
undergo phenotypic changes from M1 (tumour-killing phenotype) to
alternative M2 (tumour-promoting phenotype) [130,131]. The M1
phenotype is a pro-inflammatory state and is induced by endotoxin,
IFNγ and interleukin-1 α (IL-1α); the M2 state is anti-inflammatory
phenotype induced by IL-4, IL-10, IL-13, TGF-β and glucocorticoids
[130,131]. Changes in intracellular metabolism are crucial for the po-
larisation of TAMs from M1 to M2 state [131,130]. M1 TAMs maintain
high glycolysis and release lactate that sustains their survival in hypoxic
TME, while M2 TAMs preferably use OXPHOS and FAβO to support
their energy needs [131,130,132]. In M1 TAMs, the TCA cycle is
blocked at two different sites [130]. The cycle is first halted after the
synthesis of citrate. This leads to the accumulation of citrate, which is
critical for the synthesis of pro-inflammatory regulators such as ROS
and nitric oxide (NO) [133,130]. Cytosolic citrate participates in the
synthesis of phospholipids and prostaglandins required to sustain the
pro-inflammatory TME [134,130]. The second blockage of the TCA
cycle in M1 macrophages occurs after the production of succinate. The
accumulation of succinate plays a critical role in the activation of IL-1β
required for the transcription of HIF-1α [130,135]. In this scenario,
glutamine metabolised via TCA cycle to α-ketoglutarate and succinate
is critical for HIF-1α activation via IL-1β expression [130]. On the other
hand, M2 macrophages have intact TCA cycle and secrete IL-4 and IL-13
which inhibits the mTOR pathway leading to reduced expression of
HIF-1α and decreased expression of glycolytic and inflammatory re-
sponse genes [130,136].
TAMs increase the number, tumourigenicity and drug resistance in
CSCs through STAT3 activation [137]. In turn, CSCs induce M2 phe-
notype in TAMs and block anti-tumour CD8+ responses during che-
motherapeutic treatment [137]. Tumour cells attract M2-polarised
macrophages by secreting colony-stimulating factor (CSF), TGF-β, en-
dothelial growth factor (EGF) and chemokine ligands 2, 3, 4 and 5
[138]. On the other hand, M2 macrophages secrete IL-6, IL-10, TGF-β
and EGF, which drive CSC self-renewal by activating the STAT3/NFκB
signalling pathways [37]. Activation of these pathways stimulates ad-
ditional cytokine production and further recruitment of M2 macro-
phages [37]. In addition, M2 macrophages stimulate CD4+ Treg T cell
responses to produce an immunosuppressive microenvironment [139].
Furthermore, macrophages promote the migration of cancer cells to
distant organs and make TME amicable for CSC seeding [140]. In this
context, CSCs may dictate the remodelling of metastatic niches by re-
cruiting specific stromal cells and re-arranging the composition of ex-
tracellular matrix [139].
Beside macrophages, natural killer (NK) cells make an important
component of the innate immune system. Natural killer group 2
member D (NKG2D) is an activating receptor on NK cells and CD8+T
cells. NKG2D binds to major histocompatibility complex (MHC) mole-
cules on antigen-presenting cells in response to a co- stimulatory sig-
nalling [141]. Loss of NKGD ligand expression and MHC class 1 has
been observed in cancer cells, and was associated with resistance to
immune-mediated killing [142]. Glioblastoma CSCs, which did not
express protective amounts of human leukocyte antigen (HLA) class 1
molecules but expressed high amount of CD226/DNAM-1 activating NK
receptors, have been a target of NK cells [143]. It has been reported that
CSCs downregulate MHC class I expression to sustain their growth in
TME and the antigen presenting machinery for MHC class I and class II
are also downregulated in CSCs when compared to non-cancer stem
cells [144].
A number of recent studies have evaluated the role of EMT and
immune regulatory phenotypes in CSCs [145]. In breast cancer, EMT
induction by overexpression or activation of SNAIL makes breast cancer
cells resistant to cytotoxic T cells (CTL) through induction of autop-
hagy, as targeting BECN1 (an autophagy inducer) restored CTL-medi-
ated tumour cell lysis without any effect on the morphology or the
expression of EMT markers [146]. Furthermore, antigen-specific (MHC
class 1) CTL-mediated immunotherapy has been shown to confer on
surviving cervical tumour cells CSC phenotype by hyper-activating
Nanog/T cell leukaemia/lymphoma 1 A (TCL1 A)/Akt signalling
[147,148]. These immune-edited surviving tumour cells exhibited EMT
phenotype characterised by increased expression of BMI1 and TWIST1
(protein products of proto-oncogenes), suggesting that adaptation of
EMT/CSC phenotype may be central players in the failure of current
immunotherapies [147,148]. Another recent study on breast cancer
utilised expression profiling of a large breast cancer data set and
showed significant correlation between the expression of programmed
death ligand-1 (PD-LI) and embryonic stem cell factors Oct4A, Nanog
and BMI1 [149]. The expression of Oct4A and Nanog could be induced
by ectopic PD-L1 expression in these tumour cells while down-
regulation of PD-L1 expression resulted in loss of self-renewal cap-
abilities of breast CSCs in vitro and in vivo [149]. These studies clearly
indicate the immune regulatory roles of CSCs. Fig. 1 depict the effect of
the TME on cancer and CSC metabolism.
3. Ovarian cancer and CSC metabolism
3.1. TME of ovarian cancer
Ovarian cancer (OC) often termed as a ‘silent killer’ is the most le-
thal of all gynaecological malignancies and is the fifth leading cause of
cancer death among women worldwide [150,151]. Vague clinical
manifestation attributes to late-stage diagnosis in approximately 75% of
OC patients [151]. Standard treatment consisting of debulking surgery
followed by chemotherapy treatment offers marginal benefit to improve
clinical outcomes [152]. Due to the prevalent off-target effects of che-
motherapy and high incidence of chemoresistance, 80% of women
eventually relapse within 6–20 months and have a 5-year survival rate
of only 30–40% [152,151].
Progression in advanced-stage OC includes ovarian and in-
traperitoneal metastases, which in approximately 40% of the newly
diagnosed cases results in the accumulation of peritoneal malignant
tumour fluid (ascites). Ascites contain single and cluster of cells com-
monly known as ‘spheroids’ floating or embedded in the mesothelial
lining of the peritoneal cavity [153,154]. It has been suggested that
primary OC cells may undergo EMT during localised invasion in the
peritoneum and retain mesenchymal features in advanced tumours
[155–157]. However, OC cells floating as spheroids retain epithelial
features as evidenced by enhanced E-cadherin expression, and are able
to invade surrounding mesothelial cells [158]. Spheroids undergo re-
duced proliferation and have limited drug penetration resulting in de-
creased susceptibility to chemotherapy, mimicking traits of CSC-like
cells [159].
OC cells that are shed from the primary ovarian tumours initially
spread in the peritoneal cavity with the flow of ascites [153,160]. There
is a huge built up of ascites in some OC patients due to disruption of the
lymphatic system [153,151]. Dissemination of ovarian tumours
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through vasculature as a primary mode of cancer metastasis is rare,
although dissemination to pelvic and para aortic lymph nodes can be
involved in some cases [161]. Ascites has a complex heterogeneous
picture consisting of single cells and multicellular aggregates or
spheroids, cancer-associated immune cells, CAFs, myeloid cells and
activated mesothelial cells [153]. The main site of OC dissemination
however, is the omentum, a large fat pad that extends from the stomach
and covers majority of the abdominal organs, and serves as a storage
site for energy-loaded lipids for metastatic cells [162]. In mouse
models, homing of metastatic OC cells towards omentum was attributed
to growth factors such as IL-8, IL-6, monocyte chemoattractant protein-
1 (MCP-1) and adiponectin secreted by omental adipocytes. Omental fat
cells also activate p38 and STAT3 pathways in OC cells creating an ideal
TME for sustaining cancer growth [163].
3.2. Ovarian CSCs, cancer and CSC metabolism
3.2.1. Ovarian CSCs
The literature on ovarian CSCs is relatively extensive [164–167].
Numerous studies have shown the existence of ovarian CSCs by FACS-
sorting cells from primary tumours or cell lines using cell surface and
intracellular markers known to annotate tumours of other origins. The
studies on cell surface markers include CD44, epithelial cell adhesion
molecule (EpCAM), CD133, CD117, CD90 (Thy-1) and CD24
[168–171]. Among the intracellular markers, aldehyde dehydrogenase
(ALDH) has commonly been used [172]. CSCs termed as ‘side popula-
tion’ have also been isolated from ovarian tumours and cell lines based
on their abilities to efflux the DNA binding dyes [173,174]. Even
though the CSCs FACS-sorted on the basis of specific markers or side
population demonstrated typical ‘CSC phenotype’ (ability to self-renew,
resistance to therapy, develop tumours in very small numbers ∼100
cells, etc), none of the tumours developed from the sorted CSCs or side
populations mimicked OC progression in humans [164,165]. These
inconsistencies occur due to the use of subcutaneous modes of cancer
cell transplantation into immunocompromised mice. This mode of
transplantation fails to recapitulate the true metastatic features of OC
that occurs mainly in the peritoneum involving ovaries, adjacent organs
(extra-ovarian pelvic organs, colon, bladder, liver, etc.) and in certain
cases in the presence of ascites [151,153]. In addition, im-
munocompromised mouse model lacks an immunogenic response that
further imposes discrepancies in mechanisms of tumour initiation and
dissemination. However, the tumour-initiating cell frequency that relies
on CSCs was consistent in primary ovarian tumours and omental me-
tastases within the same patients, but varied significantly between
different high-grade tumours [175]. This may suggest that the ‘CSC
phenotype is an intrinsic property of ovarian tumours’ and is retained
with the progression of tumour in patients which varies between in-
dividuals.
3.2.2. Ovarian cancer cell metabolism
Few recent studies have demonstrated distinct glycolytic as well as
OXPHOS-dependent metabolic features of ovarian tumours [176].
Hexokinase 2 (HK2), a key glycolytic enzyme that phosphorylates
glucose into glucose-6-phosphate is highly expressed in epithelial
ovarian tumours; while its expression is considerably lower in normal,
benign and borderline tumours [176,177]. In another recent study, high
expression of HK2 was associated with chemoresistance in ovarian tu-
mours [178]. Loss of fructose-2,6-bisphosphatase 3 (PFKFB3), a key
enzyme which regulates phosphofructokinase-1 (PFK-1) and catalyses
the conversion of fructose 6-phosphate and ATP into fructose 1,6- bi-
sphosphate and adenosine triphosphate (ADP) enhances mitotic OC cell
death in response to paclitaxel [179]. In addition, high-grade ovarian
tumours overexpress 3-phosphoinositide-dependent protein kinase-1
(PDK1), an enzyme that regulates the effect of various growth factors
[180]. The expression of PDK1 is absent in normal ovaries and low in
benign tumours [180]. This suggests that tumourigenic mechanisms
may be sustained via glycolysis in OC. Consistent with that, chemo-
sensitive OC cell lines display a distinct glycolytic phenotype while
their chemoresistant counterparts exhibit a high metabolic phenotype
and retain a flexibility to switch between glycolytic and OXPHOS
pathways as an energy source [176]. This may indicate a survival
adaptation to cytotoxic stress associated with chemoresistance.
Fig. 1. Dynamic exchange between the tumour cells, CSCs and immune cells. The progressing tumours and CSCs exert both inhibitory and stimulatory effects on the
immune system. Loss of IFN-γ expression and increased PD-L1 levels in CSCs create an immunosuppressive TME by inhibiting immunogenicity in cytotoxic T cells and
other immune cells. CSCs induce M2 phenotype (tumour- promoting) in TAMs through STAT3 activation. TAMs secrete IL-6 and IL-10 to drive CSC self- renewal.
CSC-derived TGFβ signalling induces Tregs to promote tumour growth and suppress anti-tumour immunity. TME-induced metabolic reprogramming results in
increased OXPHOS with elevated FA and glutamate production. CSCs also have the ability to switch to anaerobic glycolysis where low levels of ROS enable CSC
maintenance and self-renewal.
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Besides glycolysis, lipid metabolism has been strongly associated
with OC progression [162]. Overexpression of FASN, a key enzyme in
lipogenesis, correlates significantly with tumour grade and FIGO sta-
ging in OC [181]. Patients with high FASN expression have shown to
have poor overall survival rate [181]; inhibition of FASN in platinum-
resistant OC cells was shown to reverse cisplatin resistance [182]. Re-
cent in vitro co-culture studies of OC cells and adipocytes have shown
transfer of lipid droplets from adipocytes to cancer cells [163]. This
observation is consistent with the presence of lipid droplets in OC cells
that borders adipocytes in human tumours [163,162]. The lipid trans-
ferred from adipocytes to cancer cells accelerated FAβO in tumour cells
as shown by their enhanced proliferation in vitro [163,162]. On the
other hand, cancer cells impose metabolism in adipocytes by inducing
hydrolysis of triglycerides stored in adipocyte lipid droplets into free FA
and glycerol that then acts as fuel for cancer cells [163]. This increased
intake of lipids by the cancer cells from the adipocytes leads to the
transformation of omentum into a solid tumour by a process known as
‘omental caking’ [183,162]. Hence, metastatic ovarian tumours that
grow in adipose-rich TME have greater rates of FAβO to provide a
readily available source of energy in the metastatic niche [162].
3.2.3. Ovarian CSC metabolism
Metabolism in ovarian CSCs remains to be explored. Like CSCs from
other sources, ovarian CSCs display a flexible metabolism depending on
their TME and nutritional requirement [184]. A recent study using in
vitro cell culture has shown that when CSCs of CD44+CD117+ pheno-
type FACS-sorted from OC primary culture were detached from the
monolayer condition to a suspension state, reprogramed their meta-
bolism from glycolysis to TCA cycle and had an active lipid metabolism
compared to adherent cultures [185]. Consistent with that, ovarian
CSC-like spheroid cells were shown to rely on anaerobic glycolysis and
pentose phosphate pathway (PPP) and have decreased TCA cycle
compared to their parental cells [186]. This increased flux through the
PPP is essential for NADPH synthesis to promote FA synthesis, a feature
that is more prominent in spheroids compared to parental anchorage-
dependent cells [186]. In another study, CD44+CD117+ CSCs isolated
from the ascites of OC patients showed enhanced glucose uptake ca-
pacity and exhibited metabolic profile dominated by OXPHOS with
higher ROS production and elevated membrane potential. Additionally,
these cells were more susceptible to OXPHOS inhibitors compared to
CD44+CD117+ non-CSCs [187]. These cells also had an elevated PPP
not typical for cells with preference for OXPHOS than glycolysis and
expressed high level of FAβO enzymes [187]. Enhanced PPP in CSCs
may be a prerequisite for the sustenance of ROS homoeostasis between
CSCs and bulk of the tumour cells, and for the protection of CSCs
against ROS damage or irreversible damage of mitochondria during
cytotoxic stress [187]. Higher expression of FAβO enzymes in
CD44+CD117+ CSCs may indicate reliance of this pathway as a source
of metabolites required for enhanced OXPHOS activity [187]. A recent
study showed that ovarian CSCs displaying ALDH+CD133+ phenotype
has significantly increased levels of unsaturated lipids compared to non-
CSCs [188]. Higher lipid saturation level was found in CSC-enriched
spheroids compared to monolayer primary cells, where inhibition of
lipid desaturases effectively eliminated CSCs, inhibited sphere forma-
tion in vitro and tumour initiation in vivo [188]. We have previously
demonstrated that following cisplatin or paclitaxel treatment, surviving
residual population of human OC cells displayed chemoresistant and
CSC phenotypes [189,190]. In addition, xenotransplantation studies
using chemotherapy-treated surviving HEY cells generated significantly
larger tumour burden compared to untreated cells [191]. Moreover, a
greater proliferative and tumourigenic capacity was retained with an
enhanced cancer stemness profile as evidenced by the significantly in-
creased activation of phosphorylated STAT3 and elevated expression of
Ki67, CA125, CD117 and Oct4 [79,80]. Even though these studies did
not look into the metabolic prolife of chemotherapy-treated cells, re-
cently we have shown that knockdown of stem cell factor Oct4A sig-
nificantly decreased Glut-1 expression in a mouse xenograft, suggesting
an association between glucose metabolism and Oct4A expression
[192].
4. Metabolic and immunological signatures in chemoresistant
ovarian CSCs: a proof-of- concept in vitro and in vivo models
Recently by using genomic and proteomic platforms we have re-
ported the differential genomic and proteome profile of ascites-derived
tumour cells isolated from ovarian cancer patients before chemotherapy
treatment (CN) and at recurrence (CR) [193,194]. CR ascites-derived
tumour cells display features consistent with CSC phenotype, including
high expression of CD133, characteristic markers of drug resistance
(such as MSH6, ABCC4, etc), OXPHOS and FA-driven metabolic phe-
notypes and loss of interferon and HLA-dependent immune signatures
[194]. The key OXPHOS and FA-associated enzymes significantly up-
regulated in CR versus CN cells and the loss of interferon and HLA-
associated proteins are described in Table 1. Among them, the greatest
magnitude of change is seen in acetyl-CoA carboxylase (ACACA) {Rsc:
CR/CN=12.2; [194]}, a cytosolic enzyme that is responsible for the
conversion of acetyl-CoA to malonyl-CoA, which is an essential sub-
strate for the biosynthesis of FAs and subsequently triglycerides,
phospholipids, lipoproteins and substrates for the mevalonate pathway
[195]. ACACA reprograms the metabolism of head and neck squamous
cell carcinomas in response to cetuximab by inhibiting glycolysis and
activating AMPK-dependent lipogenesis [195]. Inhibition of ACACA
inhibited ALDH+breast CSCs and also impeded the ability of HER2 to
increase the ALDH+population [196], suggesting that ACACA may be
a requisite for breast CSCs survival.
The next significantly upregulated enzyme on the list is asparagine
synthetase (ASNS) {Rsc: CR/CN=10.6; [194]}, a cytosolic enzyme
that converts aspartate to asparagine to support cell proliferation. Most
somatic cells express ASNS in sufficient amounts but some cancer cells
in suspension culture were shown to express ASNS several-fold higher
compared to adherent cells in culture [225]. Moreover, ASNS expres-
sion has also been associated with androgen-resistant prostate cancer,
and downregulation of ASNS restores sensitivity to androgens in re-
sistant cells in vitro and in vivomouse models [226]. In breast carcinoma
mouse model, circulating tumour cells isolated from mouse blood
showed elevated levels of ASNS compared to the parental cell line in
culture, suggesting that ASNS activity may favour survival of ancho-
rage-independent free-floating cells. In addition, limiting asparagine by
ASNS knockdown, L-asparaginase treatment or dietary asparagine re-
striction in a breast cancer model reduced metastasis without affecting
the growth of primary tumour, whereas increased dietary asparagine or
enforced ASNS expression promoted metastatic progression by upre-
gulating EMT-related proteins [227]. These evidences suggest that the
bioavailability of asparagine may be crucial for metastatic progression.
Farnesyl diphosphate farnesyltransferase (FDFT1), also known as
squalene synthase, was significantly up regulated in CR compared to CN
ascites-derived tumour cells {Rsc: CR/CN=6.6; [194]}. FDFT1 is the
enzyme that initiates the shift from acetyl-CoA to cholesterol synthesis
[201], which is essential to maintain the membrane raft-associated
cholesterol in cancer cells [228]. mRNA expression of FDFT1 correlated
with the aggressiveness of prostate cancer [229], and FDT1 was shown
to have a role in promoting FA synthesis through upregulation of FASN
[230]. This suggests a potential involvement of FDFT1 in maintaining
cholesterol and FA synthesis essential for energy consumption and
membrane fluidity of cancer cells.
The peroxisome proliferator-activated receptor-α (PPARα)-
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interacting cofactor (PRIC)-295 (PRIC-295) {Rsc: CR/CN=4.6; [194]}
was significantly elevated in CR compared to CN samples. PRIC295 is a
novel coactivator protein that enhances the activation of PPARα and
PPARγ and plays a key role in regulating the genes for FA oxidation
[204,205]. In addition to PRIC-295, propionyl-CoA carboxylase α and β
(PCCA and PCCB) chains {Rsc: CR/CN=3.5 and 3.3; [194]} were also
upregulated in CR versus CN population. Elevated PCCA and PCCB
indicate flux of propionyl-CoA, a major catabolite of essential amino
acids (for example leucine, isoleucine, valine, etc) and odd chain FA,
through succinate in the mitochondria to sustain the activity of OX-
PHOS cycle [206,207]. Significantly elevated expression of FA desa-
turase (FADS2) {Rsc: CR/CN=2.6 [194];} was observed in CR vs CN
ascites-derived tumour cells. It has been shown that lipid desaturation
is an important factor in promoting tumour development and recur-
rence in cancer, and is required to maintain stemness in OC
[188,208,209,231–234]. In addition, pyruvate dehydrogenase phos-
phatase regulator subunit (PDPR) {Rsc: CR/CN=2.4 [210];} and ATP-
citrate lyase (ACLY) {Rsc: CR/CN=2.3 [211–214];} were also sig-
nificantly elevated in CR versus CN cells. While mitochondrial PDPR
regulates the pyruvate dehydrogenase (PDH) complex for the conver-
sion of pyruvate to acetyl-CoA, ACLY is a key enzyme linking glucose
metabolism to lipid synthesis, which catalyses the conversion of citrate
to acetyl-CoA [211]. These observations suggest that in CSC-like CR
cells, a flux through acetyl-CoA may regulate primarily de novo FA
synthesis, FAβO and subsequent cholesterol synthesis that are the es-
sential regulatory pathways to sustain greater energy demands for the
biomass production of free-floating CSCs in the ascites. These data are
consistent with our previous findings where we demonstrated that the
tumour cell content of CR ascites is several-fold greater than CN ascites
[158]. Table 1 also shows a list of proteins that were downregulated in
CSC-like CR cells compared to CN cells. This includes interferon-in-
duced protein with tetratricopeptide repeats 2 (IFIT2) [Rsc: CR/CN=
-5.7], stimulator of interferon protein-2 (TMEM173) [Rsc: CR/CN=
-2.8], interferon induced GTP binding protein 2 (Mx2) [Rsc: CR/CN=
-2.1], HLA-C [Rsc: CR/CN= -30.9 and HLA-B [Rsc: CR/CN= -54.5]
proteins. IFIT2, TMEM173 and MX2 are involved in interferon (IFN)
type 1, 11 and 111 responses and have key roles in innate cell immunity
[215–224,235]. Loss of these important components of the immune
system suggests that interferon signalling in CR population is severely
compromised, which may be responsible for the immunosuppressive
ascites-mediated TME in OC [153,160]. In this context, IFN signalling
can boost MHC expression in tumour cells and hamper the recruitment
of immune effector cells [218]. Massively decreased HLA-C and HLA-B
protein expression in CR cells may occur due to immunocompromised
IFN-associated signalling in CR cells. A recent report has shown that
glioblastoma CSCs have weak expression of MHC-I, MHC-II molecules
compared to non-CSCs of the same origin, and this expression cannot be
rescued by inducing IFN signalling [144]. This indicates a permanent
potential loss of IFN signalling in this subtype of CSCs. Dysfunctional
immune system in ovarian cancer patients occur due to im-
munosuppressive TME. This was attributed to lipid-mediated loss of T
cell function [236] and secretion of gangliosides by OC cells in TME,
which contributes to T cell disarmament [237,238]. In addition, these
tumours have high expression of IDO, which adds another layer of T
cell-disabling function through nutrient deprivation for T cells in
ovarian TME [239]. A recent study has shown induced conversion of
cytotoxic CD8+T cells to CD8+Tregs cells influenced by ovarian
TME [240]. These cells had enhanced expression of CTLA-4 and FoxP3
and compromised naïve CD4+ effector T cell function through TGF-β
and IFNγ mediated pathways.
Using in vitro OC cell lines and a mouse xenograft model, we de-
monstrate that treatment with chemotherapy (cisplatin or paclitaxel)
results in a CSC phenotype (enhanced mRNA expression of Oct4A, Sox-
2, CD133 and EpCAM) with enhanced expression of chemoresistance
markers [enhanced mRNA expression of DNA excision repair protein
(ERCC1), class III β-tubulin (TUBB3), MSH6, ABCC4] in residual sur-
viving cells (Fig. 2). The enhanced mRNA expression of CSC and re-
sistant markers was consistent with increased mRNA levels of ACACA,
ASNS, FDFTI and PD-L1 in chemotherapy-treated vs untreated cell lines.
The increased trend of these markers in response to chemotherapy was
observed in three OC cell lines, SKOV3, OVCAR5 and HEY, but was not
always significant (Fig. 2). Sustained PD-L1 expression is a prerequisite
for the effectiveness of PD-1/PD- L1 therapy in patients [241]. PD-L1
expression also promotes Oct4 and Nanog expression in breast cancer
stem cells by sustaining the activation of PI3K/Akt pathway [149]. In
addition, PD-L1 expression was significantly higher on primary cells
isolated from patients with JAK2V617 F mutation- driven myeloproli-
ferative neoplasms compared to healthy individuals; and declined upon
JAK2 inhibition [242]. These patients have constitutively active JAK2/
STAT3 pathway in their neoplastic cells, monocytes, megakaryocytes
and platelets. We have previously shown that ascites-derived tumour
cells from CR patients have significantly enhanced activated JAK2/
STAT3 pathway compared to tumour cell derived from CN patients
[243]. We have also shown that JAK2/STAT3 pathway is activated in
OC cells in response to chemotherapy treatment [80,81]. It remains to
be determined if the co-expression of PD-L1 is dependent on JAK2/
STAT3 pathway; and can be sustained in drug-treated CSC-like cells
when the direct cytotoxic effect of chemotherapy is relieved. However,
ovarian tumours that harbour PD-L1 expression respond better to cur-
rent immune checkpoint immunotherapies than tumours lacking PD-L1
expression [244].
We also provide preliminary data to demonstrate that the profile of
CSC-like phenotype, in relation to ACACA and ASNS expression, can be
retained in a mouse xenograft model of HEY human ovarian cancer cell
line that we have described before [245] (Fig. 3). In brief, nineteen days
after the intraperitoneal injection of HEY cells (5× 106/mouse), mice
were divided into three groups (n = 5/group). The first group of mice
was control untreated; the second and third group of mice (groups 1
and 2) received intraperitoneal injection of paclitaxel (15mg/kg body
weight) weekly. Treatment in groups 1 and 2 was maintained until the
endpoint of control untreated mice was reached. At this point, mice in
control and group 1 (paclitaxel-treated) were euthanised. Treatment in
group 2 was terminated as control group, but the mice in this group
were allowed to survive until the experimental end-point for each
mouse was achieved (paclitaxel-recurrent). These mice survived two
weeks longer than control untreated and paclitaxel-treated mice [81].
Control untreated mice developed the largest tumour burden com-
pared to all groups [81]. There was a significantly lower tumour burden
in group 1 compared to control untreated mice, while the tumour
burden in group 2 was similar to the control group but significantly
higher than the group 1 mice [81]. Immunohistochemical analysis of
mouse xenografts showed significant elevation in CSC-associated Oct4
staining in group 2 compared to group 1 and control groups (Fig. 3).
However, the expression of CSC-associated marker CD117 (c-kit) was
significantly elevated in groups 1 and 2 compared to the control un-
treated group (Fig. 3). The expression of ACACA and ASNS were also
significantly elevated in group 2 compared to control and group 1 but
the expression of Glut-1 was significantly downregulated in group 1
mice. However, there was no significant difference in the Glut-1 ex-
pression between control and group 2 mice (Fig. 3).
Collectively, these observations from proteomic profiling of CR
versus CN populations, in vitro chemotherapy-treated ovarian cancer
cell lines and mouse xenograft model provide ‘proof-of- concept’ data
suggesting that chemotherapy treatment may induce a metabolic plas-
ticity in ‘ovarian CSC-like recurrent cells’ (CR cells) which favours
pathways reliant on OXPHOS-mediated lipid metabolism. This is
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achieved via upregulation of key enzymes in various metabolic path-
ways. Enhanced expression of PDPR in CR cells indicates that the mi-
tochondrial production of acetyl-CoA from pyruvate (product of aerobic
glycolysis) may be inhibited. Under these conditions, pyruvate (and
glutamate) generated through aerobic glycolysis may be converted to
α-ketoglutarate, through glutamine transaminase (GPT2), which is re-
shuffled into TCA cycle for the continuation of OXPHOS. Pyruvate
uptake, essential for the synthesis of acetyl-CoA and continuity of mi-
tochondrial function, was shown to be significantly high in invasive
ovarian cancer cells under anchorage- independent condition, com-
pared to cells cultured in a monolayer situation [246]. On the other
hand, pyruvate is also converted into lactate, which through acid-
ification of the ascites microenvironment suppresses the anti-cancer
immune response by inhibiting T cell function [236] and/or polarisa-
tion of T cells to Tregs. Acidification of ascites microenvironment also
sustains therapy resistance CR cells by providing them with a growth
advantage [23].
High expression of ACACA in CR cells drives the conversion of
acetyl-CoA to malonyl-CoA to feed into TCA cycle. Upregulation of
PCCA and PCCB in CR cells catalyses the conversion of propionyl- CoA
to succinyl-CoA to further fuel the TCA cycle. In addition, citrate is
metabolised by ACLY to produce acetyl-CoA. Excess acetyl-CoA in the
cytoplasm can be metabolised to form squalene, which subsequently
promotes cholesterol synthesis with the elevated level of FDFT1 in CR
cells. On the other hand, heightened level of FADS2 promotes the
desaturation of FA. Acyl-CoA produced from FA synthesis enters FAβO
to facilitate the production of acetyl-CoA in the mitochondria for the
ongoing sustenance of metabolic cycle. Elevated level of ASNS converts
aspartate to asparagine to support nucleotide synthesis. Hence, it can be
postulated that recurring CR OC cells may undergo metabolic repro-
graming more towards OXPHOS-dependent acetyl-CoA-driven lipid
metabolism to sustain their rapidly expanding proliferative growth in
an ascites microenvironment. Fig. 4 depicts this scenario of ovarian
CSCs in the ascites-rich TME.
5. Conclusion and future perspectives
This review provides a snapshot of metabolic changes in cancer cells
and CSCs and summarises our current understanding of the metabolic
regulation in OC cells and associated CSCs. We also present ‘proof-of-
concept’ data that suggests that chemotherapy-resistant recurrent OC
cells (CR) portray characteristics of CSCs, and display OXPHOS-de-
pendent acetyl-CoA-driven lipid metabolism. Our data is consistent
with previous studies, which have revealed similar flexibility in the
metabolic phenotype of CSCs [184,187]. Chemoresistant OC cells
maintain highly active flexible metabolic phenotype compared to their
chemosensitive glucose-dependent counterparts [246]. In addition,
clinical responsiveness to platinum in patient-derived OC cells was
shown to depend on glucose metabolism [246]. Platinum-sensitive cells
appear to rely more on glucose metabolism compared to their resistant
Fig. 2. mRNA expression of markers for chemoresistance and CSC-phenotype, ACACA, ASNS, FDFT1 and PD-L1 in in vitro ovarian cancer cell lines treated with
chemotherapy. Ovarian cancer cell lines (SKOV3, OVCAR5 and HEY) were treated for 3 days with IC50 concentration of chemotherapy cisplatin (Cis) [2 μg/ml, 3 μg/
ml and 3.5 μg/ml respectively] or paclitaxel (Pac) [0.5 ng/ml, 0.5 ng/ml and 1 ng/ml respectively] (n=3). mRNA expression of chemoresistance markers [DNA
excision repair protein (ERCC1), class III β-tubulin (TUBB3), MSH6, ABCC4], CSC markers (Oct4A, Sox-2, CD133 and EpCAM), ACACA, ASNS, FDFTI and PD-L1 was
performed as by qRT-PCR as described previously [80,81]. Data are shown as the mean ± SEM (n= 3) and analysed using One-Way Anova (each cell line analysed
on its own) (* p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. CD133 * p < 0.05 only significant to control when student t-test is performed.
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counterparts, which have more active and diverse metabolic regulation.
It is yet unclear if this metabolic alteration is responsible for the che-
moresistant phenotype or if oncogenes/tumour suppressor genes in
combination with altered, chemotherapy-induced microenvironmental
factors drive this metabolic adaptation. This highlights the need to
develop combined metabolic targeting which would circumvent the
metabolic flexibility induced by the TME and also chemotherapy- in-
duced changes in CSCs. In addition, pharmacological agents, which
would boost immune responses, should also be considered. The use of
therapies, which could increase the efficacy of immunotherapies
through novel checkpoint blockade, or T cells directed against CSC-
associated antigens, may represent future avenues for treating cancer
patients [244]. Interestingly, Oct4 reactive CD4+ and CD8+ T cells
were detected in healthy individuals and patients with OC [247]. The
use of DC-loaded Nanog-specific peptides as a vaccination strategy to
evoke a potent anti-tumour immune response against CSCs has been
proposed [248]. These strategies may result in immunological memory,
which may control newly formed CSCs, thereby preventing disease
recurrence [248]. Hence, targeting the metabolic properties of CSC that
is associated with tumour recurrence and overall survival of patients
would require careful design of strategies that will simultaneously
target all metabolic compartments in TME.
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